ArticleMolecular neurobiology2025
Investigation of the Protective Effects of Aripiprazole on Methylphenidate-induced Neurotoxicity in Rats.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ambroxol's Role in PTZ-Induced Anxiety-Like Conditions in Mice: Targeting Neuroinflammation and Oxidative Stress via In Vivo and In Silico Approaches.Molecular neurobiology · 2025Article
- A study on neurotransmitter levels in rats with Tic disorder treated with aripiprazole.Frontiers in neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Methylphenidate (MPH) serves as a frequently utilized stimulant in the treatment of attention deficit hyperactivity disorder (ADHD). However, long-term administration of this medication has been linked to neurotoxic sequels such as cognitive decline and increased oxidative stress, especially in the hippocampus. In contrast, aripiprazole (ARP), an atypical antipsychotic, has shown promise in providing neuroprotection and reducing inflammation. This research seeks to investigate the protective role of ARP on MPH-induced neurotoxicity in rats. A total of 40 male Wistar rats participated in this study, which were organized into five groups. All the experimental groups received daily intraperitoneal injections of MPH at 10 mg/kg, combined with varying doses of ARP at 3, 10, and 30 mg/kg for 21 days. Behavioral assessments included the open field test and forced swimming test to evaluate motor activity and depressive-like behaviors, as well as the inhibitory avoidance test for cognitive function. Seizure susceptibility was assessed using pentylenetetrazol (PTZ). Following these evaluations, hippocampal tissues were collected for biochemical analysis (oxidative stress markers and neurotrophic factor) and histopathological studies. ARP at specific doses significantly mitigated locomotor activity impairment, depressive-like behaviors, and memory deficits induced by chronic MPH administration. Additionally, ARP reduced seizure susceptibility compared to the MPH-treated group. Biochemical analyses indicated that ARP decreased oxidative stress markers, including malondialdehyde (MDA) and myeloperoxidase (MPO), while enhancing levels of glutathione and the expression of brain-derived neurotrophic factor (BDNF), nuclear factor erythroid 2-related factor 2 (NRF2), and protein kinase B (Akt) in hippocampus. Aripiprazole reduces behavioral and biochemical deficits from chronic MPH use in rats, suggesting it may help mitigate adverse effects of long-term MPH treatment.
Indexed as
Identifiers
40299297What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.